行情

LCI

LCI

Lannett Co
NYSE

实时行情|Nasdaq Last Sale

1.450
-0.100
-6.45%
盘后: 1.430 -0.02 -1.38% 16:18 01/21 EST
开盘
1.610
昨收
1.550
最高
1.610
最低
1.430
成交量
60.95万
成交额
--
52周最高
10.70
52周最低
1.430
市值
6,279.10万
市盈率(TTM)
-0.1511
分时
5日
1月
3月
1年
5年
Lannett Company gets FDA OK for clinical study on biosimilar insulin glargine
Lannett Company (NYSE:LCI) is trading ~4.5% higher in the pre-market after announcing that the FDA had concluded its safety review for the company’s Investigational New Drug (IND) application for biosimilar insulin glargine.
Seekingalpha · 1天前
BRIEF-Lannett Announces FDA Completes Review Of Investigational New Drug (IND) Application For Biosimilar Insulin Glargine
reuters.com · 1天前
LANNETT ANNOUNCES FDA COMPLETES REVIEW OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE
Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that they have completed the safety review of the Investigational New Drug (IND) application for biosimilar insulin glargine, a prod...
PR Newswire · 1天前
Lannett Says FDA Completes Safety Review for Biosimilar Insulin Glargine Product
MT Newswires · 2天前
BRIEF-Lannett Co Announces Submission Of Investigational New Drug (IND) Application For Biosimilar Insulin Glargine
reuters.com · 2021/12/20 11:55
Lannett Announces Submission Of Investigational New Drug Application For Biosimilar Insulin Glargine
Lannett Company, Inc. (NYSE:LCI) today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of biosimilar insulin
Benzinga · 2021/12/20 11:53
LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE
Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of biosimilar insulin glargine, a product the company is co-de...
PR Newswire · 2021/12/20 11:52
HealthInvest Partners AB Buys Harmony Biosciences Holdings Inc, Rigel Pharmaceuticals Inc, ...
GuruFocus News · 2021/11/08 13:38
更多
财务预测
实际值（美元）
预测值（美元）
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解LCI最新的财务预测，通过LCI每股收益，每股净资产，每股现金流等数据分析Lannett Co近期的经营情况，然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

中性

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

0.00%强力推荐
0.00%买入
100.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测LCI价格均价为5.00，最高价位5.00，最低价为5.00。
最高5.00
均价5.00
最低5.00
现价1.450
EPS
实际EPS
预期EPS
-0.24-0.15-0.070.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
机构持股
总机构数: 162
机构持股: 3,173.14万
持股比例: 73.28%
总股本: 4,330.42万
类型机构数股数
增持
17
60.47万
建仓
6
229.01万
减持
33
188.50万
平仓
28
163.42万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.92%
制药与医学研究
-1.11%
高管信息
Non-Executive Chairman/Independent Director
Patrick Lepore
Chief Executive Officer/Director
Timothy Crew
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance
John Kozlowski
Chief Operating Officer/Vice President
John Abt
Senior Vice President
Maureen Cavanaugh
General Counsel
Samuel Israel
Director
Jeffrey Farber
Independent Director
John Chapman
Independent Director
David Drabik
Independent Director
Melissa Rewolinski
Independent Director
Paul Taveira
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
LCI 简况
Lannett Company Inc是一系列医疗适应症的品牌药品仿制药的开发商、制造商、营销商和分销商。该公司的产品包括氟奋乃静片剂，用于管理精神障碍的表现；泊沙康唑DR片剂，用于预防人类真菌感染；维拉帕米SR片剂是一种钙通道阻滞剂，用于治疗高血压、心律失常和心绞痛；哌醋甲酯CD胶囊，用于治疗注意力缺陷多动障碍；奥美拉唑胶囊，用于治疗食道和胃溃疡的某些疾病；泮托拉唑钠DR片剂是一种质子泵抑制剂，适用于治疗食道的某些疾病和病理性分泌过多疾病和舒马普坦鼻喷雾剂，用于偏头痛发作的急性治疗。

微牛提供Lannett Company, Inc.(NYSE-LCI)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的LCI股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易LCI股票基本功能。